QTRX completed its acquisition of Akoya Biosciences with substantially higher revenue but deteriorating profitability and a significant cash position decline.
The acquisition integration appears complete based on language changes from "planned" to "anticipated benefits," but the financial impact shows concerning trends with gross profit declining despite revenue growth, suggesting margin compression. The nearly 50% decline in cash reserves combined with substantially higher liabilities indicates the acquisition was costly and may strain near-term liquidity.
Revenue grew substantially while gross profit declined meaningfully, indicating significant margin deterioration likely from the Akoya acquisition integration. The balance sheet shows clear acquisition impacts with inventory growing notably, total liabilities increasing substantially, and cash reserves declining by nearly half. Operating expenses increased across both SG&A and R&D, reflecting the expanded combined entity but putting additional pressure on already compressed margins.
Current liabilities surged 78% — significant near-term obligations; verify ability to meet short-term debt.
Inventory surged 67.1% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Strong top-line growth of 64.5% — accelerating demand or successful expansion into new markets.
Liabilities grew 60.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Cash declined 47.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 41.6% — monitor working capital adequacy and short-term liquidity.
SG&A up 35.8% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Capex reduced 22.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
R&D investment increased 15.6% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →